Application of CLN-IgG/Pritumumab against COVID-19 Infectivity from the Aspect of Tumor-PIVIEMT Scheme

Authors: Hugwil AV*

DOI: 10.23880/oajco-16000169

Volume 5, Issue 1

Abstract

The touch/tactile sensor PIEZO1/2 and vimentin network is the critical conduit for COVID-19 virus infectivity. Coordination of PIEZO1/2 and vimentin network in regard to EMT/MET which is actual accordance of PIVEMT is critical for stem cell sustenance and wound healing of the injured cells and tissues in inflammation. On the contrary PIVIEMT discordance, deteriorated PIEZO1/2-Vimentin network, provokes pathogenic symptoms such as severe autoimmunopathies. From this aspect imminent treatment is necessary to recuperate the patients from onset of pathogens and/or neoplasms by use of chaperonic antibody that is able to restore/resile the pathogenic PIVIEMT as seen in the clinical trials against brain tumor patients with repetitive administration of the natural human monoclonal antibody CLN-IgG/Pritumumab. Targeting the virus conduit with the chaperonic antibody is highly expected for not only shutting down the virus infectivity but also augmentation of the antibody-directed vaccination against virus propagation.

Keywords: Anti-Cancer Antibody; Human monoclonal antibody ClN-IgG/Pritumumab; Idiotypic antibody; Vimentinepitope; EMT/MET; Cancer Stem Cell; Prion-amyloid; Brain Tumor; COVID-19

View PDF